Ultragenyx Pharma (RARE) Posts Smaller-than-Expected Q2 Loss

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/23/2026

1. DECK
2. WDC
3. RNG
4. BYD
5. FIX
6. SPOT
7. BE
8. FCNCA
9. TSCO
10. WCN

Go back to Ultragenyx Pharma (RARE) Posts Smaller-than-Expected Q2 Loss

Ultragenyx Reports Second Quarter 2018 Financial Results and Corporate Update

August 2, 2018 4:05 PM EDT

NOVATO, Calif, Aug. 02, 2018 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare diseases, today reported its financial results and corporate update for the quarter ended June 30, 2018.

Enthusiasm from the XLH community has resulted in promising commercial uptake of Crysvita in the United States, and momentum continues to grow among both pediatric and adult patients, said Emil D. Kakkis, M.D., Ph.D., Chief Executive Officer and President of Ultragenyx. In the second half of the year we will... More